3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
50
Cyclophosphamide
25
Carboplatin
25
Gemcitabine
20
Cisplatin
19
fludarabine
18
Nivolumab
17
Paclitaxel
16
Bevacizumab
15
Specimen Handling
14
Fluorouracil
11
Magnetic Resonance Spectroscopy
10
aldesleukin
9
Oxaliplatin
9
Irinotecan
9
Docetaxel
9
Biopsy
9
olaparib
8
Trastuzumab
8
durvalumab
7
atezolizumab
7
Hyperthermic Intraperitoneal Chemotherapy
7
Albumin-Bound Paclitaxel
7
Taxes
6
Leucovorin
6
Ipilimumab
6
Interleukin-2
6
Cetuximab
6
Capecitabine
6
130-nm albumin-bound paclitaxel
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
AZD9833
×
Gastrointestinal
×
Clear all
NCT04644068
2026-02-19
PETRA
AstraZeneca
Phase 1/2
Active not recruiting
702 enrolled